107 related articles for article (PubMed ID: 17476915)
21. Why does C-reactive protein predict coronary events?
Kushner I; Elyan M
Am J Med; 2008 Jul; 121(7):e11. PubMed ID: 18589040
[No Abstract] [Full Text] [Related]
22. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
Davidson MH
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
[No Abstract] [Full Text] [Related]
23. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease.
Sniderman AD; Holme I; Aastveit A; Furberg C; Walldius G; Jungner I
Am J Cardiol; 2007 Jul; 100(2):217-21. PubMed ID: 17631073
[TBL] [Abstract][Full Text] [Related]
24. [Benefits and risks of the new markers for early diagnosis of myocardial infarction].
Hamm C
Internist (Berl); 2006 Jun; 47 Suppl 1():S60. PubMed ID: 17598195
[No Abstract] [Full Text] [Related]
25. Low diurnal variability of apolipoprotein A1, apolipoprotein B and apolipoprotein B/apolipoprotein A1 ratio during normal sleep and after an acute shift of sleep.
Larsson A; Carlsson L; Axelsson J
Clin Biochem; 2008 Jul; 41(10-11):859-62. PubMed ID: 18387362
[TBL] [Abstract][Full Text] [Related]
26. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS).
Holme I; Aastveit AH; Jungner I; Walldius G
J Intern Med; 2008 Jul; 264(1):30-8. PubMed ID: 18298486
[TBL] [Abstract][Full Text] [Related]
27. Lack of apolipoprotein A1 in patients recovering from myocardial infarction.
Acoltzin C; Lezama Y
Am J Cardiol; 1990 Jul; 66(1):124. PubMed ID: 2113763
[No Abstract] [Full Text] [Related]
28. Decreased apolipoprotein A-I and B content in plasma of individuals with sickle cell anemia.
Sasaki J; Waterman MR; Cottam GL
Clin Chem; 1986 Jan; 32(1 Pt 1):226-7. PubMed ID: 3079682
[No Abstract] [Full Text] [Related]
29. Apolipoprotein A-I concentrations in serum: a pragmatic approach to assessing risk of heart disease.
Lippi U; Bertolini D; Graziani MS
Clin Chem; 1990 Apr; 36(4):701. PubMed ID: 2108831
[No Abstract] [Full Text] [Related]
30. Influence of haemodialysis on high-sensitivity C-reactive protein, lipoprotein(a), apolipoproteins A and B.
Lippi G; Tessitore N; Salvagno GL; Bedogna V; Bassi A; Montagnana M; Lupo A; Guidi GC
Clin Biochem; 2007 Nov; 40(16-17):1336-8. PubMed ID: 17826754
[TBL] [Abstract][Full Text] [Related]
31. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
Walldius G; Jungner I
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotiens and prediction of fatal myocardial infarction.
Wald NJ; Law M; Haddow JE; Craig WY
Lancet; 2002 May; 359(9320):1864. PubMed ID: 12044410
[No Abstract] [Full Text] [Related]
33. Cardiovascular risk--what should be measured?
Frantz ID
Mayo Clin Proc; 1986 May; 61(5):396-8. PubMed ID: 3702499
[No Abstract] [Full Text] [Related]
34. [Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].
Onat A; Ozhan H; Can G; Hergenç G; Karabulut A; Albayrak S
Anadolu Kardiyol Derg; 2007 Jun; 7(2):128-33. PubMed ID: 17513206
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus.
Matsumoto K; Fujita N; Nakamura K; Senoo T; Tominaga T; Ueki Y
Diabetes Res Clin Pract; 2008 Oct; 82(1):93-7. PubMed ID: 18684539
[TBL] [Abstract][Full Text] [Related]
36. PCI-related myocardial infarction. The princess on the pea or routine benchmarking of interventions.
Dellborg M
Scand Cardiovasc J; 2009 Jun; 43(3):150-1. PubMed ID: 19199122
[No Abstract] [Full Text] [Related]
37. Apoprotein A and B values in children.
Oggero R; Mostert M; Bonaudo R
Eur J Pediatr; 1988 Nov; 148(2):173. PubMed ID: 3234446
[No Abstract] [Full Text] [Related]
38. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
39. Familial combined hyperlipidemia and insulin resistance.
Frohlich J; Sniderman A
Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2100-1. PubMed ID: 11742892
[No Abstract] [Full Text] [Related]
40. Post-infarction risk is higher with low LDL? Pondering global risk, treatment bias and the nature of outcome events.
Wexler O; Schwartz RG
Cardiol J; 2009; 16(3):195-6. PubMed ID: 19437392
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
